China Rural Hypertension Control Project

Summary

China Rural Hypertension Control (CRHC) Project is a cluster randomized trial that will test the effectiveness of a village doctor-led multifaceted intensive blood pressure intervention on hypertension control in 18 months (Phase 1), cardiovascular disease risk in 36 months (Phase 2), and all-cause dementia in 48 months (Phase 3) among patients with hypertension in rural China. An extended observational follow-up, the CRHCP post-intervention observational follow-up study, will be conducted at Year 7 to evaluate long-term effects.

Conditions

• Hypertension

Interventions

OTHER

Village-doctor-led multifaceted intervention

* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension * Using hypertension control rate as one of the metrics for incentive supplements to village doctors * Providing discounted or free antihypertensive medications to patients with hypertension * Training village doctors to measure blood pressure according to a standard protocol * Training village doctors to use a simple stepwise protocol for hypertension treatment * Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence * Providing free blood-pressure monitor and training to patients for home blood pressure measurement * Encouraging lifestyle change and medication adherence * Connecting patients through WeChat or telephone for group social support

Sponsors & Collaborators

• Tulane University

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Disease Control and Prevention Centre of Liaoning Province

  collaborator UNKNOWN

• Chaoyang Central Hospital

  collaborator OTHER

• Hanzhong People's Hospital

  collaborator UNKNOWN

• Disease Control and Prevention Centre of Chaoyang City

  collaborator UNKNOWN

• Shengjing Hospital

  collaborator OTHER

• First Hospital of China Medical University

  lead OTHER

Principal Investigators

• Yingxian Sun, MD, PhD · First Hospital of China Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-05-08

Primary Completion

2026-01-31

Completion

2026-12-31

Countries

• China

Study Locations